Apollo Endosurgery Upgraded To Overweight From Neutral At Piper Sandler

Piper Sandler analyst Adam Maeder upgraded Apollo Endosurgery to Overweight from Neutral with a price target of $5, up from $2.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.